Tech Company Financing Transactions

Inversago Pharma Funding Round

On 10/17/2022, Inversago Pharma raised $69 million in Series C financing from New Enterprise Associates, adMare BioInnovations and Amgen Ventures.

Transaction Overview

Company Name
Announced On
10/17/2022
Transaction Type
Venture Equity
Amount
$69,000,000
Round
Series C
Proceeds Purpose
The company intends to use the funds to move Its program, INV-202, into a Phase 2 clinical trial in Diabetic Kidney Disease in Q4 2022.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Place Ville Marie 1670
Montreal QC, H3B 2B6
Canada
Phone
Undisclosed
Email Address
Overview
A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), Type-1 Diabetes (T1D), obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).
Profile
Inversago Pharma LinkedIn Company Profile
Social Media
Inversago Pharma Company Twitter Account
Company News
Inversago Pharma News
Facebook
Inversago Pharma on Facebook
YouTube
Inversago Pharma on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
François Ravenelle
  François Ravenelle LinkedIn Profile  François Ravenelle Twitter Account  François Ravenelle News  François Ravenelle on Facebook
Chief Financial Officer
Micheline Beauvais
  Micheline Beauvais LinkedIn Profile  Micheline Beauvais Twitter Account  Micheline Beauvais News  Micheline Beauvais on Facebook
Chief Medical Officer
Christine McCarthy
  Christine McCarthy LinkedIn Profile  Christine McCarthy Twitter Account  Christine McCarthy News  Christine McCarthy on Facebook
VP - R & D
Caroline Fradette
  Caroline Fradette LinkedIn Profile  Caroline Fradette Twitter Account  Caroline Fradette News  Caroline Fradette on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/17/2022: Mobility Work venture capital transaction
Next: 10/17/2022: Surge Therapeutics venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary